Navigation Links
Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak
Date:10/14/2009

PRINCETON, N.J., Oct. 14 /PRNewswire/ -- Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in the connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Gilead Sciences (Nasdaq: GILD), Sinovac Biotech (Amex: SVA), Dynavax Technologies (Nasdaq: DVAX), Hemispherx BioPharma (Amex: HEB), BioCryst Pharmaceuticals (Nasdaq: BCRX) and several others.

After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.

To receive a free, 23-page report offering in depth analysis of the various participants in the vaccine and antiviral market, as well as some peripheral plays focusing directly on the impact of the current H1N1 swine flu pandemic, please visit the following link:

http://www.bullmarket.com/digest/signup.php?refer=pr1_swineflu

The report covers these topics and more recent reports:

-- Which small-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak and which are riding on the hype?

-- What sets Sinovac apart from other small caps pursuing vaccines and treatments to fight swine flu? How robust is Sinovac's array of products?

-- Is BioCryst likely to see revenue from its flu treatment during this flu season? How does BioCryst's peramivir fare against established drugs Tamiflu and Relenza? What are the downside risks facing BioCryst after its strong run higher?

-- Is Dynavax a real swine flu play? What do Dynavax investors need to know about the company's swine flu efforts?

-- How important is Tamiflu to Gilead's business? What are the mechanics of Gilead's Tamiflu royalty arrangement with Roche? What are the threats to Tamiflu's dominance in the antiviral market?

About Weekly Digest:

Weekly Digest is a free publication offering first-rate stock research, analysis, and commentary that is independently published by leading investment services. Subscribers receive a weekly newsletter as well as regular Special Reports, such as the new report Investor Essentials: Picking Winners for Pandemic Profits.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, +1-888-278-5515

SOURCE Indie Research Advisors, LLC


'/>"/>
SOURCE Indie Research Advisors, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
2. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
3. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
4. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
5. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
6. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
9. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
10. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
11. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):